WO2011132966A2 - 경피 흡수 제제 - Google Patents
경피 흡수 제제 Download PDFInfo
- Publication number
- WO2011132966A2 WO2011132966A2 PCT/KR2011/002887 KR2011002887W WO2011132966A2 WO 2011132966 A2 WO2011132966 A2 WO 2011132966A2 KR 2011002887 W KR2011002887 W KR 2011002887W WO 2011132966 A2 WO2011132966 A2 WO 2011132966A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- transdermal absorption
- resin
- absorption preparation
- layer
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to transdermal absorption preparations.
- the present invention relates to a transdermal absorption preparation for treating neurological disorders containing ropinillol or a salt thereof, wherein the percutaneous absorption formulation has excellent skin permeation performance of ropinillol or its salt without any side effects caused by an initial increase in blood concentration. .
- Ropinirol is a dopamine receptor agonist that is selective for the D2 dopamine receptor and has a high affinity for the D3 dopamine receptor.
- Ropinirol is a dopamine receptor agonist that facilitates dopamine delivery.
- a drug delivery system for ropinirole is used as a transdermal absorption agent to continuously deliver a certain amount of drug to reduce side effects due to an initial increase in blood concentration.
- Transdermal administration systems do not pass the liver first, unlike conventional oral or injectable forms, which prevents the drug from turning into inactive metabolites by the liver and does not pass through the digestive system, thus preventing There is no problem of minimizing and affecting drug absorption by conditions in the digestive tract.
- the blood concentration of the drug can be kept constant for a long time, and unlike oral or injectable drugs, side effects due to high blood concentration can be prevented. There is an advantage that can be facilitated.
- transdermal administration has the advantage that the medication is convenient for patients who can not swallow the drug.
- the skin acts as a barrier to the influx of foreign substances, and thus, the skin itself acts as a speed limiting process in the permeation process of the drug, thereby limiting the permeability of the drug. Therefore, there are a limited number of drugs that can deliver the drug to the body using the skin.
- the drug in the form of a hydrophilic drug or salt has a problem that it is difficult to be absorbed through the skin compared to the general drug because of its large polarity.
- Representative examples include a method of increasing drug concentration in a transdermal administration system to increase the partition from the transdermal administration system to the skin, and a method of smoothing drug delivery to the skin using ultrasound or electric current. Can be.
- percutaneous absorption preparations are administered through the skin and thus require some properties, unlike those used in general oral or inhalation, suppositories, and ointments.
- the bases used in transdermal absorbent preparations must have sufficient adhesiveness to adhere the preparation to the skin for extended periods of time at room temperature, have no skin irritation, and have no residue on the skin when removing the preparation from the skin. It is true.
- the present invention is easy to absorb the drug through the skin, it is attached to the skin
- the present invention seeks to provide a novel transdermal absorbent preparation that has sufficient adhesive properties to the skin and is not irritating to the skin and leaves no residue on the skin when removing the preparation from the skin.
- the present invention provides a transdermal absorbent preparation comprising a drug-containing adhesive layer, a drug protective layer, and a release layer, wherein the drug-containing adhesive layer is ropinirole or salts thereof, rubber, tackifying resin, and antioxidant. And a transdermal absorption accelerator.
- the present invention also provides a transdermal absorption preparation comprising a drug-containing adhesive layer, a drug protective layer, and a release layer, wherein the drug-containing adhesive layer includes ropinillol or a salt thereof, an acrylic adhesive, an anti-crystallization agent, and a transdermal absorption accelerator.
- a transdermal absorption preparation comprising a drug-containing adhesive layer, a drug protective layer, and a release layer, wherein the drug-containing adhesive layer includes ropinillol or a salt thereof, an acrylic adhesive, an anti-crystallization agent, and a transdermal absorption accelerator.
- the percutaneous absorption preparation of the present invention is used for the treatment of neurological disorders such as Parkinson's disease or restless leg syndrome, there is an advantage in that the skin permeation performance of the drug is excellent without the side effects caused by the initial blood concentration rise.
- transdermal absorbent preparations of the present invention have sufficient adhesive properties to adhere to the skin when used and are not irritating to the skin and leave no residue on the skin when the preparation is removed from the skin.
- FIG. 1 is a cross-sectional view showing a transdermal absorbent preparation according to an embodiment of the present invention, in Figure 1 1 is a drug-containing adhesive layer, 2 is a drug protective layer, 3 means a release layer.
- Figure 2 is a cross-sectional view showing a transdermal absorbent preparation according to another embodiment of the present invention
- 1 is a drug-containing adhesive layer
- 2 is a drug protective layer
- 3 is a release layer
- 4 means an adhesive support layer.
- the present invention provides novel transdermal absorption preparations.
- transdermal absorbent preparation of the present invention is a transdermal absorbent preparation comprising a drug-containing adhesive layer, a drug protective layer, and a release layer, wherein the drug-containing adhesive layer is ropinirole or a salt thereof, rubber, tackifying resin, A transdermal absorption preparation comprising an antioxidant and a transdermal absorption accelerator.
- the drug-containing adhesive layer contains lopinirol or a salt thereof and is in direct contact with the skin to adjust the drug release rate.
- the drug-containing adhesive layer is a matrix-like monolayer containing lopinirol or a salt thereof as a drug, and the peeling layer is peeled off and then directly contacted with the skin by a pressure-sensitive adhesive system.
- the drug-containing adhesive layer has a thickness of 30 to 120 ⁇ m, preferably 50 to 80 ⁇ m. If less than 30 ⁇ m drug concentration is too high, the drug is crystallized in the formulation, and the adhesion is too low, the adhesion is low. If it exceeds 120 ⁇ m low concentration of the drug is difficult to achieve proper skin penetration.
- Ropinirole [4- (2-di-n-propylaminoethyl) -2- (3H) -indolone] is an indole derivative that is selective for the D2 dopamine receptor and has a high affinity for the D3 dopamine receptor. It is an agent.
- Ropinirol is a dopamine receptor agonist having the structure of Formula 1 and having a molecular weight of 260.38 to facilitate dopamine delivery.
- the salt of the ropinirole is an inorganic acid such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, phosphorous acid, aliphatic monocarboxylic acid, aliphatic dicarboxylic acid, alkanoic acid substituted with phenyl group, It may be, but is not limited to, a salt obtained from the group consisting of non-toxic organic acids such as hydroxy alkanoic acid and hydroxy alkanedioic acid, aromatic acids, aliphatic sulfonic acids and aromatic sulfonic acids.
- the ropinirole or salt thereof may be included in an amount of 5 to 30% by weight, preferably 10 to 20% by weight, based on the total weight of the drug-containing adhesive layer.
- the ropinirole or salt thereof may be included in less than 5% by weight there is a problem that does not reach the appropriate level of skin permeability, when contained in excess of 30% by weight has a high drug concentration, there is a problem such as crystal formation and adhesion decrease of the drug.
- the rubber has a low glass transition temperature (Tg), is thermoplastic, and is used to serve as an adhesive due to excellent mechanical properties.
- Tg glass transition temperature
- the rubber alone may have a low adhesive force, and thus, a desired adhesive property may be secured by adding a tackifying resin or the like.
- the rubber is a styrene-ethylene-isoprene-styrene copolymer, a styrene-butadiene-styrene copolymer, a styrene-butadiene copolymer, a styrene- 1 or 2 or more selected from the group consisting of styrene-isoprene copolymer, styrene-isoprene-styrene copolymer, silicone rubber, and polyisobutylene, Any biocompatible rubber can be used without limitation.
- the rubber may be included in 10 to 50% by weight based on the total weight of the drug-containing adhesive layer.
- the rubber When used in less than 10% by weight, there is a problem that the role of the pressure-sensitive adhesive is insignificant, so that the mechanical properties are weak, and when used in excess of 50% by weight, the viscosity is high and the adhesive strength is lowered.
- the tackifying resin is used to obtain the desired adhesive strength in an appropriate amount when the rubber alone is difficult to obtain the desired adhesive strength.
- the tackifying resin is rosin glycerin ester Resin, hydrogenated rosinglycerin ester resin, rosin pentaerythritol ester resin, hydrogenated rosinpentaerythritol ester resin, alphamethylstyrene resin, alicyclic saturated hydrocarbon resin having 5 to 9 carbon atoms, aliphatic hydrocarbon resin having 5 to 9 carbon atoms, aromatic hydrocarbon
- One, two or more selected from the group consisting of a resin, a hydrogenated dicyclopentadiene resin, a terpene resin, a coumarone indene resin, and a terpene phenol resin may be used, but is not limited thereto.
- the tackifying resin may be included in 5 to 70% by weight based on the total weight of the drug-containing adhesive layer. When used in less than 5% by weight, there is a problem that the effect of improving the adhesive strength of the formulation by the formulation of the tackifying resin is insufficient, and when used in excess of 70% by weight there is a problem in that the skin irritation property when peeling the formulation.
- the antioxidant is used to prevent the polymer material used in the adhesive layer from reacting with light or oxygen, thereby causing the molecules to be cut or crosslinked, thereby changing the molecular structure, molecular weight, and the like.
- BHT butylated hydroxytoluene
- Iganox® 565 manufactured by Ciba-Geigy Co., Ltd.
- Iganox 1010 manufactured by Ciba-Geigi Co., Ltd.
- Iganox 1076 Ciba-Geigi Co., Ltd.
- Antioxidant can be used more than 0% by weight or less than 2% by weight based on the total weight of the drug-containing adhesive layer, preferably 0.1 to 1% by weight. Antioxidants can suppress the generation of radicals that can be produced by light or oxygen in polymer materials, so that a small amount of the antioxidant can achieve the desired purpose.
- the percutaneous absorption enhancer is used to increase the efficiency of delivery to the skin of lopinirol or its salts.
- the percutaneous absorption accelerator may be included in 5 to 20% by weight based on the total weight of the drug-containing adhesive layer. When used in less than 5% by weight can not sufficiently achieve the desired skin permeation promoting effect, when used in excess of 20% by weight there is a problem that the adhesive property deteriorates.
- a cohesive enhancer such as silica dimethyl silylate may be further used in an amount of 0.1 to 10% by weight based on the total weight of the drug-containing adhesive layer.
- a cohesive strengthening effect When included in less than 0.1% by weight is a cohesive strengthening effect is weak and when included in excess of 10% by weight there is a problem such as a decrease in adhesion.
- the drug protective layer is used to prevent the back penetration of the drug contained in the drug-containing adhesive layer.
- the thickness of the drug protective layer is not particularly limited, but it is preferable to use it at 5 to 500 ⁇ m in view of ease of application and ease of manufacture.
- the drug protective layer is a film in which a polyester film, a polypropylene film, a polyethylene film, a polyester film, a polyacrylonitrile film, a metal film-deposited polyester film is used alone, or multiple films selected from two or more of them are deposited. (multilayered film) may be used, or a polyester film laminated with a nonwoven fabric may be used.
- the release layer is used to separate and immediately remove the drug-containing adhesive layer to the skin immediately before use. It is preferable to use the thickness of a peeling layer at 15-500 micrometers from a viewpoint which considered ease of peeling and manufacturing ease.
- a silicone resin or a fluorine resin is coated on a polymer film selected from the group consisting of polyester, polyvinyl chloride, polyvinylidene chloride, polyethylene terephthalate and copolymers thereof.
- a release paper coated with a silicone resin or a fluorine resin may be used on the quality paper or glassine paper in which polyolefin is laminated as the release layer.
- the transdermal absorbent preparation may further comprise an adhesive support layer to prevent skin dropout of the preparation due to the release of excessive moisture or sweat and to maintain skin adhesion to increase the reliability of the preparation.
- the thickness of the adhesive support layer is preferably 5 to 500 ⁇ m in view of ease of adhesion and ease of manufacture.
- the pressure-sensitive adhesive support layer is a polyurethane film, a porous film, a perforated film, a fabric, a non-woven fabric and a foam (foam) is selected from the acrylic pressure-sensitive adhesive, rubber pressure-sensitive adhesive, silicone pressure-sensitive adhesive and ethylene vinyl acetate (EVA) pressure-sensitive adhesive is applied Can be used.
- transdermal absorbent preparation of the present invention is a transdermal absorbent preparation comprising a drug-containing adhesive layer, a drug protective layer, and a release layer, wherein the drug-containing adhesive layer is ropinillol or a salt thereof, an acrylic adhesive , An anti-crystallization agent, and a transdermal absorption accelerator.
- the lopinirol or a salt thereof is as described above, it may be included in 5 to 30% by weight, preferably 10 to 20% by weight relative to the total weight of the drug-containing adhesive layer.
- the drug concentration is high, there is a problem such as crystal formation of the drug or lowering the adhesion.
- the acrylic pressure-sensitive adhesive may be a functional group or one containing one or two or more functional groups selected from the group consisting of -COOH, -OH and -NH 2 , but is not limited thereto. Specific examples include acrylic acid, 2-ethylhexyl acrylate, butyl acrylate, 2-hydroxyethyl acrylate, methyl methacrylate, methyl acrylate, glycidyl methacrylate, vinyl acetate, N-vinyl-2-pi
- the polyacrylate block copolymer containing 1 or more types chosen from the group which consists of a rollidone, diacetone acrylamide, t-octyl acrylamide, 2- (dimethyl aminoethyl) methacrylate, etc. are mentioned.
- the acrylic pressure-sensitive adhesive may be included in 30 to 90% by weight, preferably 50 to 90% by weight relative to the total weight of the drug-containing adhesive layer. When included in less than 30% by weight it is difficult to obtain the desired adhesive strength, when included in excess of 90% by weight there is a problem that the concentration of the drug and other transdermal absorption accelerators or excipients is relatively low.
- the anti-crystallization agent is preferably included in 0.1 to 20% by weight based on the total weight of the drug-containing adhesive layer.
- the anti-crystallization agent is preferably included in 0.1 to 20% by weight based on the total weight of the drug-containing adhesive layer.
- cellulose systems such as polyvinylpyrrolidone and hydroxy propyl cellulose, hydroxy propyl methyl cellulose, and ethyl cellulose may be used, and polyvinyl pyrrolidone is preferable. They may also act as excipients.
- the percutaneous absorption accelerator is preferably included 5 to 20% by weight based on the total weight of the drug-containing adhesive layer. When used in less than 5% by weight can not sufficiently achieve the desired skin permeation promoting effect, when used in excess of 20% by weight there is a problem that the adhesive property deteriorates.
- the drug protective layer is used to prevent the back penetration of the drug contained in the drug-containing adhesive layer.
- the thickness of the drug protective layer is not particularly limited, but it is preferable to use it at 5 to 500 ⁇ m in view of ease of application and ease of manufacture.
- the drug protective layer includes a polyester film, a polypropylene film, a polyethylene film, a polyacrylonitrile film, a metal film deposited polyester film, a nonwoven fabric laminated polyester film and multiple films selected from two or more thereof. Any one selected from the group consisting of multilayered films can be used.
- the release layer is used to separate and immediately remove the drug-containing adhesive layer to the skin immediately before use. It is preferable to use the thickness of a peeling layer at 15-500 micrometers from a viewpoint which considered ease of peeling and manufacturing ease.
- a polymer film selected from the group consisting of polyester, polyvinyl chloride, polyvinylidene chloride, polyethylene terephthalate and copolymers thereof may be used.
- a release paper coated with a silicone resin or a fluorine resin may be used on the quality paper or glassine paper in which polyolefin is laminated as the release layer.
- the transdermal absorbent preparation may further comprise an adhesive support layer to prevent skin dropout of the preparation due to the release of excessive moisture or sweat and to maintain skin adhesion to increase the reliability of the preparation.
- the thickness of the adhesive support layer is preferably 5 to 500 ⁇ m in view of ease of adhesion and ease of manufacture.
- the pressure-sensitive adhesive support layer is a polyurethane film, a porous film, a perforated film, a fabric, a non-woven fabric and a foam (foam) is selected from the acrylic pressure-sensitive adhesive, rubber pressure-sensitive adhesive, silicone pressure-sensitive adhesive and ethyl vinyl acetate (EVA) pressure-sensitive adhesive selected from Can be used.
- foam is selected from the acrylic pressure-sensitive adhesive, rubber pressure-sensitive adhesive, silicone pressure-sensitive adhesive and ethyl vinyl acetate (EVA) pressure-sensitive adhesive selected from Can be used.
- the percutaneous absorption preparation of the present invention is designed to enable constant sustained drug release for 1 to 7 days, and the content of the drug may be differently prepared according to the area by designing the area of the preparation to 2.5 to 70 cm 2 according to the amount of drug required. Can be.
- the dissolved solution is coated on a polyester film (thickness: 75 ⁇ m) coated with a silicone resin and dried to form a drug-containing adhesive layer having a thickness of 110 ⁇ m, and then laminated on the polyester film (thickness: 12 ⁇ m) to patch.
- a polyester film thickness: 75 ⁇ m coated with a silicone resin and dried to form a drug-containing adhesive layer having a thickness of 110 ⁇ m, and then laminated on the polyester film (thickness: 12 ⁇ m) to patch.
- the dissolved solution is coated on a polyester film (thickness: 75 ⁇ m) coated with a silicone resin and dried to form a drug-containing adhesive layer having a thickness of 110 ⁇ m, and then laminated on the polyester film (thickness: 12 ⁇ m) to patch.
- a polyester film thickness: 75 ⁇ m coated with a silicone resin and dried to form a drug-containing adhesive layer having a thickness of 110 ⁇ m, and then laminated on the polyester film (thickness: 12 ⁇ m) to patch.
- the dissolved liquid was dried on a polyester film (thickness: 75 ⁇ m) coated with a silicone resin, and then coated to dry to a thickness of 110 ⁇ m.
- the patch was prepared by laminating to the following polyester film (thickness: 12 ⁇ m).
- the aqueous phase was first filled in a Franz Diffusion cell and kept at 32 ⁇ 0.5 ° C.
- the sample was then cut into rounds (area 0.64 cm 2 ) and affixed to the center of the prepared human cadaver skin epidermis, and the sampled skin was attached to Franz Diffusion. After placing the cell on the upper part of the cell, the donor part was covered and clamped, and then a permeation experiment was performed.
- the skin was used by purchasing a human cadaver skin epidermis layer, stored at -70 °C after purchase and thawed at 40 °C when used.
- the analysis was performed using HPLC, and the mobile phase was a 25:75 (volume ratio) mixture of 70 mM ammonium formate (pH 3.8) containing acetonitrile, 0.3% EDTA, and 0.005% sodium octyl sulfate.
- the injection volume was 20 ⁇ l
- the flow rate was 0.8 ml / min
- the detection wavelength was 250 nm
- the column was a C18 reversed phase column.
- Duro-tak® 387-2287, Duro-tak®87-2852 and Duro-tak®87-4098 used as the pressure-sensitive adhesive components were manufactured by National Starch Chemical (Bridgewater, NJ, USA), and SK-Dyne®.
- IC-01N (AM) was manufactured by Soken Chemical & Engineering Co., Ltd. (Takada, Toshima-ku, Tokyo, Japan).
- Comparative Examples 3 to 6 and Examples 15 to 22 were subjected to a skin permeation test in the same manner as in Examples 1 to 14 and Comparative Examples 1 and 2, and the results are shown in Table 6 below.
- the transdermal absorbent preparation of the present invention is superior to the skin penetration effect than the comparative example.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
Abstract
Description
Claims (26)
- 약물 함유 점착층, 약물 보호층 및 박리층을 포함하여 이루어지는 경피 흡수 제제로서,상기 약물 함유 점착층은 로피니롤 또는 그의 염, 고무, 점착 부여 수지, 산화방지제 및 경피 흡수 촉진제를 포함하는 것을 특징으로 하는 경피 흡수 제제.
- 약물 함유 점착층, 약물 보호층 및 박리층을 포함하여 이루어지는 경피 흡수 제제로서,상기 약물 함유 점착층은 로피니롤 또는 그의 염, 아크릴계 점착제, 결정화 방지제 및 경피 흡수 촉진제를 포함하는 것을 특징으로 하는 경피 흡수 제제.
- 제1항 또는 제2항에 있어서, 상기 경피 흡수 제제가 점착 지지층을 더 포함하여 이루어지는 것을 특징으로 하는 경피 흡수 제제.
- 제1항 또는 제2항에 있어서, 상기 로피니롤 또는 그의 염은 약물 함유 점착층 총 중량에 대해 5 ~ 30 중량%로 포함하는 것을 특징으로 하는 경피 흡수 제제.
- 제1 항에 있어서, 상기 고무는 스티렌-에틸렌-이소프렌-스티렌 공중합체, 스티렌-부타디엔-스티렌(styrene-butadiene-styrene) 공중합체, 스티렌-부타디엔(styrene-butadiene)공중합체, 스티렌-이소프렌(styrene-isoprene) 공중합체, 스티렌-이소프렌-스티렌(styrene-isoprene-styrene) 공중합체, 실리콘 고무, 및 폴리이소부틸렌(polyisobutylene)으로 이루어진 군으로부터 선택되는 1 또는 2 이상인 것을 특징으로 하는 경피 흡수 제제.
- 제1항 에 있어서, 상기 고무는 약물 함유 점착층 총 중량에 대해 10 ~ 50 중량%로 포함하는 것을 특징으로 하는 경피 흡수 제제.
- 제1항에 있어서, 상기 점착 부여 수지는 로진글리세린 에스테르 수지, 수소 첨가 로진글리세린 에스테르 수지, 로진펜타에리스리톨 에스테르 수지, 수소 첨가 로진펜타에리스리톨 에스테르 수지, 알파메틸스티렌 수지, 탄소수 5~9인 지환족 포화 탄화수소수지, 탄소수 5~9인 지방족 탄화수소 수지, 방향족 탄화수소수지, 수소 첨가 디사이클로펜타디엔 수지, 테르펜 수지, 쿠마론 인덴 수지, 테르펜 페놀 수지로 이루어진 군으로부터 선택되는 1 또는 2 이상인 것을 특징으로 하는 경피 흡수 제제.
- 제1항에 있어서, 상기 점착 부여 수지는 약물 함유 점착층 총 중량에 대해5 ~ 70 중량%로 포함하는 것을 특징으로 하는 경피 흡수 제제.
- 제1항 에 있어서, 상기 산화방지제는 부틸레이티드하이드록시톨루엔(BHT), 이가녹스565, 이가녹스 1010, 이가녹스 1076, 포스파이트계 산화방지제 및 이들의 혼합물 중 어느 하나인 것을 특징으로 하는 경피 흡수 제제.
- 제1항 에 있어서, 상기 산화방지제는 약물 함유 점착층 총 중량에 대해 0중량% 초과 2중량% 이하로 포함하는 것을 특징으로 하는 경피 흡수 제제.
- 제1항 또는 제2항에 있어서, 상기 경피흡수 촉진제는 폴리옥시에틸렌모노올레이트, 폴리글리세릴디이소스테아레이트, N-메틸-2-피롤리돈(N-methyl-2-pyrrolidone), N-카프릴릴-2-피롤리돈(N-carprylyl-2-pyrrolidone), N-도데실-2-피롤리돈(N-dodecyl-2-pyrrolidone, Lauryl pyrrolidone), 라우릴알콜, 글리세롤 라우릴알코올(glycerol lauryl alcohol), 올레일 알코올(oleyl alcohol), 이소프로필 미리스트레이트(isopropyl myristrate), 소르비탄 모노올레이트(sorbitan mono-oleate), 프로필렌 모노라우레이트(propylene monolaurate), 프로필렌 모노올레이트(propylene monooleate), 올레오일 마크로골 글리세라이드(oleoyl macrogolglyceride), 올레인산(oleic acid), 라우로일 마크로골 글리세라이드(lauroyl macrogolglyceride), 리놀레오일 마크로골 글리세라이드(linoleoyl macrogolglyceride), 프로필렌글리콜 카프릴레이트(Propylene glycol caprylate, 프로필렌글리콜 카프레이트(Propylene glycol caprate), 소르비탄 모노스테아레이트 모노올레이트(Sorbitan monostearate monooleate), 글리세롤 모노라우레이트(glycerol monolaurate), 글리세롤 모노올레이트, 프로필렌글리콜 모노라우레이트(propyleneglycol monolaurate), 프로필렌글리콜 모노카프릴레이트(propyleneglycol monocaprylate), 소르비탄 모노라우레이트(sorbitan monolaurate), 소르비탄 모노올레이트, 라우릴 락테이트(lauryl lactate), 카프릴릭 트리글리세라이드 (caprylic triglyceride), 카프릭 트리글리세라이드(capric triglyceride), 옥수수유 PEG-8 에스테르, 옥수수유 PEG-6 에스테르 및 트리아세틴으로 이루어진 군으로부터 선택되는 1 또는 2 이상인 것을 특징으로 하는 경피 흡수 제제.
- 제1항 또는 제2항에 있어서, 상기 경피 흡수 촉진제는 약물 함유 점착층 총 중량에 대해 5 ~ 20 중량%로 포함하는 것을 특징으로 하는 경피 흡수 제제.
- 제2항에 있어서, 상기 아크릴계 점착제는 관능기가 없거나 -COOH, -OH 및 -NH2로 이루어진 군으로부터 선택되는 1 또는 2 이상의 관능기를 포함하는 것을 특징으로 하는 경피 흡수 제제.
- 제2항 에 있어서, 상기 아크릴계 점착제는 약물 함유 점착층 총 중량에 대해 30~90중량%로 포함하는 것을 특징으로 하는 경피 흡수 제제.
- 제2항 에 있어서, 상기 결정화 방지제는 폴리비닐피롤리돈, 하이드록시 프로필 셀룰로오스, 하이드록시 프로필 메틸 셀룰로오스, 에틸 셀룰로오스로 이루어진 군에서 1종 이상 선택되는 것을 특징으로 하는 경피 흡수 제제.
- 제2항 에 있어서, 상기 결정화 방지제는 약물 함유 점착층 총 중량에 대해 0.1~20중량%로 포함하는 것을 특징으로 하는 경피 흡수 제제.
- 제1항 또는 제2항에 있어서, 상기 약물 보호층은 폴리에스테르 필름, 폴리프로필렌 필름, 폴리에틸렌 필름, 폴리아크릴로니트릴 필름, 금속이 증착된 폴리에스테르 필름, 부직포가 합지된 폴리에스테르 필름 및 이들 중 2종 이상 선택된 다중의 필름이 증착된 필름(multilayered film)으로 이루어진 군으로부터 선택되는 것을 특징으로 하는 경피 흡수 제제.
- 제1항 또는 제2항에 있어서, 상기 박리층은 폴리에스테르, 폴리비닐클로라이드, 폴리비닐리덴클로라이드, 폴리에틸렌테레프탈레이트 및 이들의 공중합체로 이루어진 군으로부터 선택되는 고분자 필름 상에 실리콘 수지 또는 불소 수지가 코팅된 것이거나 폴리올레핀이 적층된 상질지 또는 글라신지 상에 실리콘 수지 또는 불소 수지가 코팅된 박리지인 것을 특징으로 하는 경피 흡수 제제.
- 제3 항에 있어서, 상기 점착 지지층은 폴리우레탄 필름, 다공성 필름, 천공 필름, 직물, 부직포 및 폼(foam) 중에서 선택되는 것에 아크릴계 점착제, 고무계 점착제, 실리콘계 점착제 및 에틸렌비닐아세테이트(EVA)계 점착제 중에서 선택되는 점착제가 도포된 것을 특징으로 하는 경피 흡수 제제.
- 제1항에 있어서, 상기 약물 함유 점착층은 약물 함유 점착층 총 중량에 대해 0.1~10중량%로 응집력 강화제를 더 포함하는 것을 특징으로 하는 경피 흡수 제제.
- 제20항에 있어서, 상기 응집력 강화제는 실리카디메틸실릴레이트인 것을 특징으로 하는 경피 흡수 제제.
- 제1항 또는 제2항에 있어서, 상기 약물 함유 점착층은 두께가 30~120㎛인 것을 특징으로 하는 경피 흡수 제제.
- 제1항 또는 제2항에 있어서, 상기 약물 보호층은 두께가 5~500㎛인 것을 특징으로 하는 경피 흡수 제제.
- 제1항 또는 제2항에 있어서, 상기 박리층은 두께가 15~500㎛인 것을 특징으로 하는 경피 흡수 제제.
- 제3항에 있어서, 상기 점착 지지층은 두께가 5~500㎛인 것을 특징으로 하는 경피 흡수 제제.
- 제1항 또는 제2항에 있어서, 로피니롤 또는 그의 염을 1~7일 동안 일정한 속도로 피부를 통해 흡수시키고, 상기 로피니롤 또는 그의 염의 피부 투과 속도가 3내지 200 μg/cm2/hr인 것을 특징으로 하는 경피 흡수 제제.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201180020562.7A CN102946873B (zh) | 2010-04-23 | 2011-04-21 | 经皮吸收制剂 |
US13/642,960 US20130165875A1 (en) | 2010-04-23 | 2011-04-21 | Transdermal absorption preparation |
EP11772254.6A EP2561865A4 (en) | 2010-04-23 | 2011-04-21 | PREPARATION FOR TRANSDERMAL ABSORPTION |
JP2013506085A JP5658353B2 (ja) | 2010-04-23 | 2011-04-21 | 経皮吸収製剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100038184A KR101292768B1 (ko) | 2010-04-23 | 2010-04-23 | 경피 흡수 제제 |
KR10-2010-0038184 | 2010-04-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011132966A2 true WO2011132966A2 (ko) | 2011-10-27 |
WO2011132966A3 WO2011132966A3 (ko) | 2012-04-12 |
Family
ID=44834668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/002887 WO2011132966A2 (ko) | 2010-04-23 | 2011-04-21 | 경피 흡수 제제 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20130165875A1 (ko) |
EP (1) | EP2561865A4 (ko) |
JP (1) | JP5658353B2 (ko) |
KR (1) | KR101292768B1 (ko) |
CN (1) | CN102946873B (ko) |
WO (1) | WO2011132966A2 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140170205A1 (en) * | 2011-05-31 | 2014-06-19 | Hisamitsu Pharmaceutical Co., Inc. | Ropinirole-containing patch and package thereof |
JPWO2013081102A1 (ja) * | 2011-12-01 | 2015-04-27 | 帝國製薬株式会社 | ロピニロール含有貼付剤 |
EP2926814A4 (en) * | 2012-11-30 | 2016-04-27 | Teikoku Seiyaku Kk | ROPINIUM-CONTAINING HEFTPFLASTER |
JP2016515572A (ja) * | 2013-04-04 | 2016-05-30 | ヒュンダイ ファーム カンパニー リミテッド | 皮膚透過が改善された外用剤組成物 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2641651T3 (es) | 2011-05-31 | 2017-11-10 | Hisamitsu Pharmaceutical Co., Inc. | Parche que contiene ropinirol y envase para el mismo |
GB201120908D0 (en) * | 2011-12-06 | 2012-01-18 | Reckitt Benckiser Healthcare | Patch containing non-steroidal anti-inflammatory drug |
JP5415645B1 (ja) * | 2013-06-28 | 2014-02-12 | 久光製薬株式会社 | 貼付剤の製造方法、貼付剤及び包装体 |
KR101485822B1 (ko) * | 2014-01-22 | 2015-01-23 | 주식회사 대웅제약 | 도네페질 또는 그의 염을 함유하는 경피흡수제제 |
JP6373061B2 (ja) * | 2014-05-23 | 2018-08-15 | 帝國製薬株式会社 | 経皮投与製剤 |
WO2016052522A1 (ja) * | 2014-09-30 | 2016-04-07 | ニプロ株式会社 | 経皮投与製剤及び包装体 |
WO2016103956A1 (ja) * | 2014-12-25 | 2016-06-30 | ニプロ株式会社 | 経皮投与製剤 |
KR101937073B1 (ko) * | 2015-04-15 | 2019-01-09 | 히사미쓰 세이야꾸 가부시키가이샤 | 로피니롤 함유 첩부제 |
EP3297620A4 (en) * | 2015-06-27 | 2019-01-09 | Shenox Pharmaceuticals, LLC | TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE |
US10561603B2 (en) | 2015-06-29 | 2020-02-18 | Sekisui Chemical Co., Ltd. | Core-shell structure and topical agent |
KR101717699B1 (ko) * | 2016-02-11 | 2017-03-17 | 아이큐어 주식회사 | 카타플라스마제용 자외선 경화형 하이드로젤 수지, 하이드로젤 및 이를 포함하는 카타플라스마제 |
WO2018080214A1 (ko) * | 2016-10-31 | 2018-05-03 | 신신제약 주식회사 | 수면장애 치료용 경피흡수제제 |
KR102499141B1 (ko) * | 2016-10-31 | 2023-02-13 | 신신제약 주식회사 | 수면장애 치료용 경피흡수제제 |
KR102024996B1 (ko) * | 2017-12-27 | 2019-09-25 | 동아에스티 주식회사 | 도네페질을 함유하는 치매 치료용 경피흡수제제 |
KR102042456B1 (ko) * | 2018-03-22 | 2019-11-08 | 크리스탈지노믹스(주) | 경피흡수제제 |
KR102455157B1 (ko) * | 2018-10-31 | 2022-10-17 | 신신제약 주식회사 | 로피니롤 경피흡수제 |
WO2021054257A1 (ja) * | 2019-09-18 | 2021-03-25 | 久光製薬株式会社 | ロピニロール含有貼付剤及びロピニロールの皮膚透過性向上方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9511366D0 (en) * | 1995-06-06 | 1995-08-02 | Smithkline Beecham Plc | Novel formulations |
US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
DE10137082A1 (de) * | 2001-07-28 | 2003-02-13 | Hexal Ag | Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol |
DE10137162A1 (de) * | 2001-07-30 | 2003-02-20 | Hexal Ag | Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol |
KR20050045946A (ko) * | 2002-06-25 | 2005-05-17 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
WO2005009417A1 (en) * | 2003-07-21 | 2005-02-03 | Noven Pharmaceuticals, Inc. | Composition and method for controlling grug delivery from silicone adhesive blends |
DE10338174A1 (de) * | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
ES2596809T3 (es) * | 2004-10-08 | 2017-01-12 | Noven Pharmaceuticals, Inc. | Dispositivo de administración transdérmica de fármacos que incluye un refuerzo oclusivo |
ES2661767T3 (es) * | 2008-02-27 | 2018-04-03 | Hisamitsu Pharmaceutical Co., Inc. | Parche adhesivo para la piel y producto envasado |
-
2010
- 2010-04-23 KR KR1020100038184A patent/KR101292768B1/ko active IP Right Grant
-
2011
- 2011-04-21 CN CN201180020562.7A patent/CN102946873B/zh active Active
- 2011-04-21 JP JP2013506085A patent/JP5658353B2/ja active Active
- 2011-04-21 US US13/642,960 patent/US20130165875A1/en not_active Abandoned
- 2011-04-21 EP EP11772254.6A patent/EP2561865A4/en not_active Withdrawn
- 2011-04-21 WO PCT/KR2011/002887 patent/WO2011132966A2/ko active Application Filing
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP2561865A4 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140170205A1 (en) * | 2011-05-31 | 2014-06-19 | Hisamitsu Pharmaceutical Co., Inc. | Ropinirole-containing patch and package thereof |
US9918945B2 (en) * | 2011-05-31 | 2018-03-20 | Hisamitsu Pharmaceutical Co., Inc. | Ropinirole-containing patch and package thereof |
JPWO2013081102A1 (ja) * | 2011-12-01 | 2015-04-27 | 帝國製薬株式会社 | ロピニロール含有貼付剤 |
EP2786752A4 (en) * | 2011-12-01 | 2015-05-06 | Teikoku Seiyaku Kk | ROPINIUM-CONTAINING HEFTPFLASTER |
JP2017061580A (ja) * | 2011-12-01 | 2017-03-30 | 帝國製薬株式会社 | ロピニロール含有貼付剤 |
EP2926814A4 (en) * | 2012-11-30 | 2016-04-27 | Teikoku Seiyaku Kk | ROPINIUM-CONTAINING HEFTPFLASTER |
JPWO2014084311A1 (ja) * | 2012-11-30 | 2017-01-05 | 帝國製薬株式会社 | ロピニロール含有貼付剤 |
JP2016515572A (ja) * | 2013-04-04 | 2016-05-30 | ヒュンダイ ファーム カンパニー リミテッド | 皮膚透過が改善された外用剤組成物 |
US10292955B2 (en) | 2013-04-04 | 2019-05-21 | Hyundai Pharm Co., Ltd. | Composition for external use preparation with improved transdermal permeability |
Also Published As
Publication number | Publication date |
---|---|
EP2561865A2 (en) | 2013-02-27 |
CN102946873B (zh) | 2015-05-13 |
KR101292768B1 (ko) | 2013-08-05 |
WO2011132966A3 (ko) | 2012-04-12 |
JP5658353B2 (ja) | 2015-01-21 |
JP2013525345A (ja) | 2013-06-20 |
KR20110118525A (ko) | 2011-10-31 |
US20130165875A1 (en) | 2013-06-27 |
CN102946873A (zh) | 2013-02-27 |
EP2561865A4 (en) | 2014-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011132966A2 (ko) | 경피 흡수 제제 | |
WO2012124966A2 (ko) | 펜타닐 경피 패치제 | |
WO2012002640A2 (ko) | 도네페질을 함유하는 경피흡수제제 | |
US9622986B2 (en) | Percutaneous absorption preparation containing donepezil, and method for preparing same | |
JP5523708B2 (ja) | 親油性かつ/または低皮膚浸透性の活性物質を投与するための経皮治療システム | |
WO2009120002A2 (ko) | 도네페질을 유효성분으로 함유하는 치매 치료용 경피흡수제제 | |
JP2003511425A (ja) | 二元粘着性経皮薬物デリバリーシステム | |
EP1937226A2 (en) | Transdermal galantamine delivery system | |
WO2015111862A1 (en) | Transdermal delivery system comprising donepezil or its salt | |
US20180256562A1 (en) | Transdermal Delivery System | |
WO2012161489A2 (ko) | 리바스티그민 함유 패취 | |
CA2210711A1 (en) | Transdermal formulation | |
WO2022191675A1 (ko) | 로티고틴 함유 경피 흡수 제제 | |
WO2013028032A1 (ko) | 경피 흡수 제제 및 그 제조방법 | |
CN116036055A (zh) | 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法 | |
KR100322988B1 (ko) | 소염진통첩부제조성물및이를함유한소염진통첩부제 | |
WO2018080214A1 (ko) | 수면장애 치료용 경피흡수제제 | |
US10137098B2 (en) | Transdermal preparation | |
WO2022066987A1 (en) | Treatment of vomiting and nausea with minimum dose of olanzapine | |
WO2009119992A2 (ko) | 펜타닐을 함유한 경피 흡수제 | |
KR100439659B1 (ko) | 툴로부테롤을 함유하는 경피흡수용 패취제 | |
ZA200108512B (en) | Transdermal therapeutic system comprising a potent neuroleptic drug. | |
WO2021107341A1 (ko) | 라사길린 또는 그의 약학적으로 허용가능한 염을 함유하는 경피흡수제제 | |
TWI780179B (zh) | 含有利伐斯的明之經皮吸收型製劑 | |
JPH0748258A (ja) | 経皮投与用製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180020562.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11772254 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011772254 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013506085 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 9195/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13642960 Country of ref document: US |